620Cell-to-cell contact and extracellular matrix
interactions. Perhaps the best known of these interactionsinvolves a specific interaction between the amino-terminaldomain of versican (G1) and hyaluronan. The binding of versican to hyaluronan involves a tandem double-loopsequence in the G1 domain of versican and a stretch of fiverepeat disaccharides in hyaluronan. This interaction is stabilized by another protein—link protein—whichexhibits selective binding specificity for both hyaluronan andversican (reviewed in [57]).
In addition to hyaluronan, versican interacts with otherECM molecules such as tenascin R [58,59]. Versican inter-acts with tenascin R through the lectin-binding domain ofversican and involves protein–carbohydrate interactions.The lectin-binding domain participates in other ligandinteractions as well. For example, versican interacts withfibulin-1 and fibulin-2 [60 ,61], a growing family of ECMproteins that are expressed in particularly high levels in thedeveloping heart valve. In adults, however, fibulin-1 and -2are found associated with microfibrils that are part of elasticfibers. Versican also can interact with proteins associatedwith elastin in elastic fibers. For example, versican inter-acts with the elastic fiber-associated protein fibrillin [62 ],and versican has been shown to co-localize with elasticfibers in skin [63]. Furthermore, fibrillins bind fibulin 2, andfibulin is preferentially localized to the elastin/microfibrilinterface in some tissue, but not in others [64]. It may bethat fibulin serves as a bridge between versican and fibrillin,forming high-ordered multimolecular structures importantin the assembly of elastic fibers.
The relationship of versican to elastic fiber assembly isinteresting and unusual. For example, rat pup arterialsmooth muscle cells have high levels of tropoelastinexpression, but no detectable levels of versican synthesis,while the opposite is true for adult arterial smooth musclecells [65,66]. Furthermore, it is known that chondroitinsulfate inhibits the formation of elastic fibers, through amechanism involving interference with the binding of theelastin receptor to the surface of arterial smooth musclecells [67].
Recent studies have shed light on the relationship of versican and elastic fiber assembly. For example, we havefound that overexpressing the versican splice variant thatlacks chondroitin sulfate chains (V3) dramatically altersarterial smooth muscle cell phenotype by enhancing celladhesion, decreasing growth and migration [68 ], andupregulating tropoelastin expression [69 ]. Placement ofV3-transduced arterial smooth muscle cells into injuredblood vessels results in the formation of multiple elasticlaminae [69 ] during injury repair. Thus, it may be thatoverexpressing the form of versican that lacks chondroitinsulfate chains competes for binding sites with versican thatcontain chondroitin sulfate chains associated with hyaluronanon the cell surface. This would allow the elastin-bindingprotein to associate with the cell surface and promote elastic fiber assembly [67,69 ,70 ].
Versican plays a role in tissue remodeling of the ECM thatis associated with developmental events as well. For example, during pregnancy and involution an extensiveremodeling of the human cervical connective tissue occurs.Versican increases in this tissue during pregnancy andachieves its highest concentration in the ripe cervix immediately after vaginal delivery, but falls dramaticallyduring involution [71]. These changes in versican areopposite to what was found for collagen types I and III andthe small leucine-rich proteoglycans dEcoRIn, biglycanand fibromodulin. Thus, versican characterizes a more provisional and loosely organized ECM that accommo-dates particular development events.
Conclusions
Evidence continues to build for a role for versican in regulating the behavior of cells. It must be remembered,however, that versican probably doesn’t act alone; and thechallenge for the future will be to sort out the multitudeof versican interactions, whether they be direct or indirect,that result in specific and targeted events that eventuallycause a change in cell phenotype. While provocative evidence exists that suggests that certain domains of versican possess unique biological activities in vitro, suchdomains need to be recognized in tissues and their activities confirmed.
We are still at the ‘tip of the iceberg’ in versican research,but exciting discoveries concerning the involvement androle of versican in development and in specific diseasesare good reasons to forge ahead. Drawing upon different disciplines will be important in the future to obtain a complete picture. Hopefully, a molecular genetic approachwill uncover specific gene defects in versican or associatedproteins, or both, that will help unravel specific roles forthese molecules. Short of, or in addition to, that, we needto move towards conditional or splice-variant knockout orknock-in systems to test direct involvement of versican inkey biological events. The future of versican research isbright, and there is a light at the end of the tunnel.
Acknowledgements
I would like to thank all the members of my group and my collaborators,past and present, who have worked tirelessly to unravel the manymysteries of the biology of this fascinating molecule. Special thanks go toSusanPotter-Perigo and her son Tommy for helping with the literaturesearch to put this review together. We accessed more than 300 referenceson versican. I only wish that I could have cited them all. The author also thanks Anne Harrington for her careful preparation of thismanuscript. This review was prepared with grant support form theNational Institutes of Health (HL-18645) and the National ScienceFoundation (EEC-9529161).
References and recommended reading
Papers of particular interest, published within the annual period of review,have been highlighted as:
of special interest
of outstanding interest
1.
Margolis RU, Margolis RK: Aggrecan–versican–neurocan family proteoglycans.Methods Enzymol1994, 245:105-126.
the extracellular matrix genes, and the cell ...proteoglycan-II, glypican, and a Miscellaneous DNA...Biology of polycystic kidney disease. Lab Invest ...
this versatile kinase also enhances the activity ...[19]; the extracellular matrix protein cartilage ...a predominate role for cAMP in granulosa cell ...
Corresponding author: Jody A. Rada, Department of Anatomy and Cell Biology,...Signi?cant changes in scleral extracellular matrix synthesis, accumulation, and...
and Chris Sander Computational Biology Center, ...in a highly versatile signalprocessing unit, able...cell migration, adhesion and extracellular matrix ...
and Chris Sander Computational Biology Center, ...in a highly versatile signalprocessing unit, able...cell migration, adhesion and extracellular matrix ...
热门文档